{{Rsnum
|rsid=7658170
|Gene=SLC2A9
|Chromosome=4
|position=9964969
|Orientation=plus
|GMAF=0.4022
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=SLC2A9
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 19.5 | 46.0 | 34.5
| HCB | 0.0 | 19.0 | 81.0
| JPT | 0.0 | 14.2 | 85.8
| YRI | 54.1 | 39.7 | 6.2
| ASW | 35.1 | 57.9 | 7.0
| CHB | 0.0 | 19.0 | 81.0
| CHD | 3.7 | 22.9 | 73.4
| GIH | 5.0 | 37.0 | 58.0
| LWK | 48.1 | 41.7 | 10.2
| MEX | 19.0 | 50.0 | 31.0
| MKK | 33.5 | 49.7 | 16.8
| TSI | 15.0 | 49.0 | 36.0
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs7658170
|Name_s=
|Gene_s=SLC2A9
|Feature=
|Evidence=PubMed ID:17537913
|Annotation=Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 87. Study population/ethnicity: 87 European descent Caucasians. Significance metric(s): p = 0.00003. Type of association: FA; GN.
|Drugs=etoposide
|Drug Classes=
|Diseases=Drug Toxicity
|Curation Level=Curated
|PharmGKB Accession ID=PA165109504
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs7658170
|overall_frequency_n=54
|overall_frequency_d=128
|overall_frequency=0.421875
|n_genomes=37
|n_genomes_annotated=0
|n_haplomes=51
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}